

**DESCRIPTION**

**Source** *E. coli*-derived  
Asn36-Ser192  
Accession # P70380

**N-terminal Sequence Analysis** Asn36 & Leu40

**Predicted Molecular Mass** 18 kDa

**SPECIFICATIONS**

**SDS-PAGE** 17 kDa, reducing conditions

**Activity** Measured by its ability to induce mouse IFN- $\gamma$  secretion by activated mouse T cells. The ED<sub>50</sub> for this effect is typically 0.06-0.36 ng/mL.

**Endotoxin Level** <0.10 EU per 1  $\mu$ g of the protein by the LAL method.

**Purity** >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

**Formulation** Lyophilized from a 0.2  $\mu$ m filtered solution in PBS, EDTA and DTT with BSA as a carrier protein. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 100  $\mu$ g/mL in PBS.


**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


**DATA**

**Bioactivity**



Recombinant Mouse IL-18/IL-1F4 (Catalog #9139-IL) induces IFN $\gamma$  secretion by activated mouse T cells. The ED<sub>50</sub> for this effect is typically 0.06-0.36 ng/mL.

**SDS-PAGE**



1  $\mu$ g/lane of Recombinant Mouse IL-18 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing a single band at 18 kDa.

## BACKGROUND

Interleukin-18 (IL-18) is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes,  $\gamma\delta$  T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases. IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation (1-3). IL-18 binds to the widely expressed IL-18 R $\alpha$  which recruits IL-18 R $\beta$  to form the signaling receptor complex (4, 5). Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs (6). In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN- $\gamma$  production and the cytolytic activity of CD8<sup>+</sup> T cells and NK cells (7, 8). In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4<sup>+</sup> T cells and basophils (9, 10). In the presence of IL-1 $\beta$  or IL-23, IL-18 induces the antigen-independent production of IL-17 by  $\gamma\delta$  T cells and CD4<sup>+</sup> T cells (11). IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst (12, 13). In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis (14). Mature mouse IL-18 shares 63% and 91% amino acid sequence identity with mouse and rat IL-18, respectively (15).

## References:

1. Dinarello, C.A. *et al.* (2013) *Front. Immunol.* **4**:289.
2. Smith, D.E. (2011) *J. Leukoc. Biol.* **89**:383.
3. Gu, Y. *et al.* (1997) *Science* **275**:206.
4. Torigoe, K. *et al.* (1997) *J. Biol. Chem.* **272**:25737.
5. Cheung, H. *et al.* (2005) *J. Immunol.* **174**:5351.
6. Novick, D. *et al.* (1999) *Immunity* **10**:127.
7. Fehniger, T.A. *et al.* (1999) *J. Immunol.* **162**:4511.
8. Yoshimoto, T. *et al.* (1998) *J. Immunol.* **161**:3400.
9. Yoshimoto, T. *et al.* (2000) *Nat. Immunol.* **1**:132.
10. Kroeger, K.M. *et al.* (2009) *J. Leukoc. Biol.* **86**:769.
11. Lalor, S.J. *et al.* (2011) *J. Immunol.* **186**:5738.
12. Li, J. *et al.* (2004) *Cell. Immunol.* **227**:103.
13. Elbim, C. *et al.* (2005) *Clin. Diagn. Lab. Immunol.* **12**:436.
14. Fabbri, M. *et al.* (2015) *J. Leukoc. Biol.* **97**:665.
15. Okamura, H. *et al.* (1995) *Nature* **378**:88.